Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Anthrax toxin receptor 1 (ANTXR1), also known as tumor endothelial marker 8, is a cell surface protein found on tumor-infiltrating vessels.
• ANTXR1 is overexpressed in various human and mouse tumors, including gastric, lung, intestinal, and breast cancer.
• While its physiological role is unclear, ANTXR1 binds collagen and aids endothelial cell migration in vitro.

Purpose of the Study:

• To review the physiological functions of ANTXR1.
• To explore the role of ANTXR1 in tumor angiogenesis, growth, and metastasis.
• To summarize findings on ANTXR1's necessity for tumor-specific angiogenesis.

Main Methods:

• Review of existing literature on ANTXR1.
• Analysis of ANTXR1 expression in different tumor types.
• Examination of ANTXR1 knockout mouse models for developmental and tumor growth phenotypes.

Main Results:

• ANTXR1 knockout mice exhibit impaired melanoma growth, suggesting a role in tumor progression.
• ANTXR1 is upregulated in tumor vasculature and sometimes in tumor cells.
• Developmental angiogenesis and wound healing are unaffected in ANTXR1 knockout mice.
• Host-derived ANTXR1 promotes tumor growth, potentially via immune interactions.
• ANTXR1 appears essential for tumor angiogenesis, not physiological angiogenesis.

Conclusions:

• ANTXR1 is a key player in tumor angiogenesis and progression.
• Targeting ANTXR1, through vaccines or toxin inhibition, may offer therapeutic strategies for cancer.
• ANTXR1 represents a promising target for anti-cancer therapies focused on angiogenesis inhibition.